Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure

Under continuous long-term treatment with abo- or onabotulinum toxin type A (BoNT/A), ~10 to 15% of patients with cervical dystonia (CD) will develop neutralizing antibodies and reduced responsiveness over an ~10-year treatment period. Among the botulinum neurotoxin type A preparations so far licens...

Descripción completa

Detalles Bibliográficos
Autores principales: Hefter, Harald, Ürer, Beyza, Brauns, Raphaela, Rosenthal, Dietmar, Meuth, Sven G., Lee, John-Ih, Albrecht, Philipp, Samadzadeh, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779547/
https://www.ncbi.nlm.nih.gov/pubmed/35051021
http://dx.doi.org/10.3390/toxins14010044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779547/
https://www.ncbi.nlm.nih.gov/pubmed/35051021
http://dx.doi.org/10.3390/toxins14010044

Ejemplares similares